Publicaciones en colaboración con investigadores/as de Institute Catalá Oncología (2)

2014

  1. Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis

    Haematologica

2013

  1. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

    European Journal of Cancer, Vol. 49, Núm. 18, pp. 3780-3787